The PRAN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PRAN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PRAN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PRAN Detailed Price Forecast - CNN Money||View PRAN Detailed Summary - Google Finance|
|View PRAN Detailed Summary - Yahoo! Finance||View PRAN Stock Research & Analysis - Zacks.com|
|View PRAN Trends & Analysis - Trade-Ideas||View PRAN Major Holders - Barrons|
|View PRAN Call Transcripts - NASDAQ||View PRAN Breaking News & Analysis - Seeking Alpha|
|View PRAN Annual Report - CompanySpotlight.com||View PRAN OTC Short Report - OTCShortReport.com|
|View PRAN Fundamentals - TradeKing||View PRAN SEC Filings - Bar Chart|
|View Historical Prices for PRAN - The WSJ||View Performance/Total Return for PRAN - Morningstar|
|View the Analyst Estimates for PRAN - MarketWatch||View the Earnings History for PRAN - CNBC|
|View the PRAN Earnings - StockMarketWatch||View PRAN Buy or Sell Recommendations - MacroAxis|
|View the PRAN Bullish Patterns - American Bulls||View PRAN Short Pain Metrics - ShortPainBot.com|
|View PRAN Stock Mentions - StockTwits||View PRAN Stock Mentions - PennyStockTweets|
|View PRAN Stock Mentions - Twitter||View PRAN Investment Forum News - Investor Hub|
|View PRAN Stock Mentions - Yahoo! Message Board||View PRAN Stock Mentions - Seeking Alpha|
|View Insider Transactions for PRAN - SECform4.com||View Insider Transactions for PRAN - Insider Cow|
|View PRAN Major Holdings Summary - CNBC||View Insider Disclosure for PRAN - OTC Markets|
|View Insider Transactions for PRAN - Yahoo! Finance||View Institutional Holdings for PRAN - NASDAQ|
|View PRAN Stock Insight & Charts - FinViz.com||View PRAN Investment Charts - StockCharts.com|
|View PRAN Stock Overview & Charts - BarChart||View PRAN User Generated Charts - Trading View|
How Financially Strong Is Prana Biotechnology Limited (ASX:PBT)?
Posted on Thursday October 11, 2018
Prana Biotechnology Limited (ASX:PBT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PBT
Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA
Posted on Thursday October 04, 2018
Prana Biotechnology Ltd (PBT.AX) (PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong on Sunday, October 7th, 2018 at 1:45pm.
PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders
Posted on Sunday July 08, 2018
Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical evidence for PBT434 at the International Congress of Parkinson’s Disease and Movement Disorders® to be held in Hong Kong from October 5-9, 2018. The data to be presented will include new in-vivo evidence of the efficacy of PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for PBT434.
First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases
Posted on Tuesday July 03, 2018
Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases. The trial conducted in Melbourne, Australia is recruiting and dosing healthy adult and elderly volunteers, to ascertain the optimal drug dose.